GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ITeos Therapeutics Inc (NAS:ITOS) » Definitions » Price-to-Tangible-Book

ITeos Therapeutics (ITeos Therapeutics) Price-to-Tangible-Book : 0.77 (As of May. 06, 2024)


View and export this data going back to 2020. Start your Free Trial

What is ITeos Therapeutics Price-to-Tangible-Book?

As of today (2024-05-06), ITeos Therapeutics's share price is $12.41. ITeos Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $16.05. Hence, ITeos Therapeutics's Price to Tangible Book Ratio of today is 0.77.

The historical rank and industry rank for ITeos Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

ITOS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.68   Med: 2.02   Max: 3.67
Current: 0.77

During the past 6 years, ITeos Therapeutics's highest Price to Tangible Book Ratio was 3.67. The lowest was 0.68. And the median was 2.02.

ITOS's Price-to-Tangible-Book is ranked better than
89.53% of 1222 companies
in the Biotechnology industry
Industry Median: 2.73 vs ITOS: 0.77

A closely related ratio is called PB Ratio. As of today, ITeos Therapeutics's share price is $12.41. ITeos Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $16.05. Hence, ITeos Therapeutics's P/B Ratio of today is 0.77.


ITeos Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for ITeos Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ITeos Therapeutics Price-to-Tangible-Book Chart

ITeos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial - 3.67 2.99 1.05 0.68

ITeos Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.05 0.75 0.76 0.65 0.68

Competitive Comparison of ITeos Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, ITeos Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ITeos Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ITeos Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where ITeos Therapeutics's Price-to-Tangible-Book falls into.



ITeos Therapeutics Price-to-Tangible-Book Calculation

ITeos Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=12.41/16.051
=0.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


ITeos Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of ITeos Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


ITeos Therapeutics (ITeos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
321 Arsenal Street, Watertown, MA, USA, 02472
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Executives
Matthew Gall officer: Chief Financial Officer C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Aaron I. Davis other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Joseph Lewis other: See remarks PO BOX N7776, LYFORD BAHAMAS
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Boxer Capital, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
David Hallal director C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Michel Detheux director, officer: Chief Executive Officer C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Yvonne Mcgrath officer: VP, Research and Development C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Joanne Jenkins Lager officer: Chief Medical Officer C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Ubs Oncology Impact Fund L.p. other: X* 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2018, L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Detlev Biniszkiewicz director C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Tony W Ho director CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Robert Iannone director 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950

ITeos Therapeutics (ITeos Therapeutics) Headlines

From GuruFocus

iTeos to Present at Cowen 43rd Annual Health Care Conference

By sperokesalga sperokesalga 02-28-2023

NCR Atleos Set to Join S&P SmallCap 600

By PRNewswire 10-11-2023

iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023

iTeos to Present at SVB Securities Global Biopharma Conference

By Stock market mentor Stock market mentor 02-07-2023

iTeos to Participate in Upcoming Investor Conferences in February

By GuruFocusNews GuruFocusNews 02-10-2022